[Federal Register Volume 81, Number 171 (Friday, September 2, 2016)]
[Notices]
[Page 60710]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-21113]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Exclusive Patent License: Development of 
Integrin [alpha]v[beta]3 Antagonists for Use in Imaging and Therapy

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 
CFR part 404.7(a)(1)(i), that the National Cancer Institute (NCI) and 
the Clinical Center (CC), National Institutes of Health, Department of 
Health and Human Services, are contemplating the grant of an exclusive 
license to Advanced Imaging Projects, LLC, a company having a place of 
business in Boca Raton, FL, to practice the inventions embodied in the 
following patent applications:

Intellectual Property

    U.S. Patent No. 7,300,940, filed 4 August 2004, titled ``Integrin 
[alpha]-v [beta]-3 antagonists for use in imaging and therapy'' (HHS 
Ref. No.: E-170-2004/0-US-01);
    PCT Application No. PCT/US2005/027868, filed 3 August 2005, now 
abandoned, titled ``Integrin [alpha]-v [beta]-3 antagonists for use in 
imaging and therapy'' (HHS Ref. No.: E-170-2004/0-PCT-02);
    Switzerland Patent No. 1781622, titled ``Integrin [alpha]-v [beta]-
3 antagonists for use in imaging and therapy'' filed 4 March 2007, 
issued 18 May 2011 (HHS Ref. No.: E-170-2004/0-CH-04);
    Germany Patent No. 602005028137.1, titled ``Integrin [alpha]-v 
[beta]-3 antagonists for use in imaging and therapy'' filed 4 March 
2007, issued 18 May 2011 (HHS Ref. No.: E-170-2004/0-DE-05);
    France Patent No. 1781622, titled ``Integrin [alpha]-v [beta]-3 
antagonists for use in imaging and therapy'' filed 4 March 2007, issued 
18 May 2011 (HHS Ref. No.: E-170-2004/0-FR-060); and
    Ireland Patent No. 1781622, titled ``Integrin [alpha]-v [beta]-3 
antagonists for use in imaging and therapy'' filed 4 March 2007, issued 
18 May 2011 (HHS Ref. No.: E-170-2004/0-IE-07).
    The patent rights in these inventions have been assigned to the 
Government of the United States of America. The territory of the 
prospective exclusive license may be worldwide, and the field of use 
may be limited to ``Conjugate of Alpha-V beta-3 antagonist NIH-CC-013 
for theranostic application to diagnose, prevent and treat oncological, 
infectious, ocular and cardiovascular disorders.''

DATES: Only written comments and/or applications for a license which 
are received by the NCI Technology Transfer Center on or before 
September 19, 2016 will be considered.

ADDRESSES: Requests for copies of the patent application(s), inquiries, 
comments, and other materials relating to the contemplated exclusive 
license should be directed to: Jaime M. Greene, M.S., Senior Licensing 
and Patenting Manager, Technology Transfer Center, National Cancer 
Institute, 9609 Medical Center Drive, Rockville, MD 20850; telephone: 
240-276-6633; email: [email protected].

SUPPLEMENTARY INFORMATION: This technology concerns small molecule 
compositions that are antagonists for the receptor integrin 
[alpha]v[beta]3. Integrins are functional molecules for cell adhesion 
activity that are expressed by the majority of normal and cancer cells. 
They are trans-membrane heterodimer receptors that include two 
subunits, [alpha] and [beta] chains, that primarily allow cell adhesion 
to extracellular matrix components such as fibrillar collagen, 
vitronectin and osteopontin. This technology may be useful for the 
development of diagnostics and therapeutics for cancers and other 
conditions involving the integrin [alpha]v[beta]3.
    The prospective exclusive license will be royalty bearing and will 
comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR part 
404.7. The prospective exclusive license may be granted unless within 
fifteen (15) days from the date of this published notice, the NIH 
receives written evidence and argument that establishes that the grant 
of the license would not be consistent with the requirements of 35 
U.S.C. 209 and 37 CFR part 404.7.
    Complete applications for a license in the prospective field of use 
that are filed in response to this notice will be treated as objections 
to the grant of the contemplated Exclusive Patent License Agreement. 
Comments and objections submitted to this notice will not be made 
available for public inspection and, to the extent permitted by law, 
will not be released under the Freedom of Information Act, 5 U.S.C. 
552.

    Dated: August 29, 2016.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer 
Institute.
[FR Doc. 2016-21113 Filed 9-1-16; 8:45 am]
 BILLING CODE 4140-01-P